RT Journal Article
SR Electronic
T1 Medications that Regulate Gastrointestinal Transit Influence Inpatient Blood Glucose
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.31.24311287
DO 10.1101/2024.07.31.24311287
A1 Momenzadeh, Amanda
A1 Cranney, Caleb
A1 Choi, So Yung
A1 Bresee, Catherine
A1 Tighiouart, Mourad
A1 Gianchandani, Roma
A1 Pevnick, Joshua
A1 Moore, Jason H.
A1 Meyer, Jesse G.
YR 2024
UL http://medrxiv.org/content/early/2024/08/02/2024.07.31.24311287.abstract
AB Objective A multitude of factors affect a hospitalized individual’s blood glucose (BG), making BG difficult to predict and manage. Beyond medications well established to alter BG, such as beta-blockers, there are likely many medications with undiscovered effects on BG variability. Identification of these medications and the strength and timing of these relationships has potential to improve glycemic management and patient safety.Materials and Methods EHR data from 103,871 inpatient encounters over 8 years within a large, urban health system was used to extract over 500 medications, laboratory measurements, and clinical predictors of BG. Feature selection was performed using an optimized Lasso model with repeated 5-fold cross-validation on the 80% training set, followed by a linear mixed regression model to evaluate statistical significance. Significant medication predictors were then evaluated for novelty against a comprehensive adverse drug event database.Results We found 29 statistically significant features associated with BG; 24 were medications including 10 medications not previously documented to alter BG. The remaining five factors were Black/African American race, history of type 2 diabetes mellitus, prior BG (mean and last) and creatinine.Discussion The unexpected medications, including several agents involved in gastrointestinal motility, found to affect BG were supported by available studies. This study may bring to light medications to use with caution in individuals with hyper- or hypoglycemia. Further investigation of these potential candidates is needed to enhance clinical utility of these findings.Conclusion This study uniquely identifies medications involved in gastrointestinal transit to be predictors of BG that may not well established and recognized in clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by NIH National Center for Advancing Translational Science (NCATS), UCLA CTSI Grant Number UL1TR001881.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cedars-Sinai IRB approval was obtained for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesClinical data used for this study is not available.